| Popis: |
PUŁA, Aleksandra, KRZYSIEK, Urszula, PODGÓRSKA, Klaudia, GORCZYCA, Kamila, ARTYKIEWICZ, Klaudia, SŁUPCZYŃSKA, Aleksandra, URBAŚ, Weronika, CZARKOWSKI, Marcin, KOZIEŁ, Paweł & GRODKIEWICZ, Maria. Potential anti-cancer features of metformin. Journal of Education, Health and Sport. 2023;13(1):136-145. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2023.13.01.022 https://apcz.umk.pl/JEHS/article/view/40874 https://zenodo.org/record/7369903 The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences). Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu). © The Authors 2022; This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited. The authors declare that there is no conflict of interests regarding the publication of this paper. Received: 15.11.2022. Revised: 20.11.2022. Accepted: 28.11.2022. POTENTIAL ANTI-CANCER FEATURES OF METFORMIN Aleksandra Puła1 Wojewódzki Szpital Specjalistyczny im. Kardynała Stefana Wyszyńskiego SPZOZ w Lublinie https://orcid.org/0000-0001-9001-5051, e-mail: aleksandrapula@gmail.com Urszula Krzysiek2 Szpital Solec Spółka z Ograniczoną Odpowiedzialnością w Warszawie https://orcid.org/0000-0002-4712-2334, e-mail: urszula.krzysiek@onet.eu Klaudia Podgórska3 Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie https://orcid.org/0000-0002-5109-900X, e-mail: kpodgorska06@gmail.com Kamila Gorczyca4 Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie https://orcid.org/0000-0002-7976-0509, e-mail: kamila.gorczyca@o2.pl Klaudia Artykiewicz5 Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie https://orcid.org/0000-0003-2912-4691, e-mail: klaudiaartykiewicz@gmail.com Aleksandra Słupczyńska6 Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie https://orcid.org/0000-0003-3615-002X, e-mail: olaslup@gmail.com Weronika Urbaś7 Medical University of Lublin https://orcid.org/0000-0002-5260-2172, e-mail: weronikaurbass@gmail.com Marcin Czarkowski8 Medical University of Lublin https://orcid.org/0000-0001-5663-2574, e-mail: marcin.czarkowski98@gmail.com Paweł Kozieł9 Medical University of Lublin https://orcid.org/0000-0001-6069-6028, e-mail: pawelkoziel61@gmail.com Maria Grodkiewicz10 Medical University of Lublin https://orcid.org/0000-0002-6243-9102, e-mail: marysiagrodkiewicz@gmail.com ABSTRACT INTRODUCTION AND PURPOSE: Metformin is one of the most frequently prescribed medications in the whole world. This lipophilic biguanide is widely used as a first-line medicine for patients suffering from type 2 diabetes mellitus because of its high effectiveness in monotherapy, and in connection with other antidiabetic drugs. Glucose-lowering properties of metformin were initially used only in the therapy of type 2 diabetes mellitus, but some data indicate that these properties might state an alternative in the prevention or treatment of some cancers both among diabetic and non-diabetic patients. STATE OF KNOWLEDGE: Metformin molecular mechanisms of action were thoroughly investigated, differentiated, and described, but in the context of the glucose-lowering effect. As a multiway drug, used mainly in diseases characterized by an increased level of glucose in the blood, numerous medical trials were conducted to find other treating properties of metformin. Recently, a few reports presented the potential connection between using metformin in the prevention and treatment of neoplasms in the same mechanisms. The scientists analyzed the influence of metformin’s action on various cancers and drew conclusions. The research on potential anti-cancer features of metformin was conducted for a relatively short period and still presents a challenge to scientists. CONCLUSIONS: The aim of this review is to gather current knowledge and present the latest discoveries about potential anti-cancer features of metformin. We discuss the potential underlying molecular mechanisms of metformin’s action in the human body and indicate the connection between the prevention and treatment of neoplasms. Additionally, we point out the exact cancers in which metformin might play a significant role. KEYWORDS:metformin; cancer; AMPK; type 2 diabetes mellitus; prevention; treatment. |
